- Vor Bio (Vor 2.0) has been rebuilt around **telitacicept**, a dual **BAFF/APRIL inhibitor** licensed from RemeGen in **late June**, securing global rights ex-China.  **[1817229_2144716_0]** 
- Telitacicept is the most advanced BAFF/APRIL inhibitor globally, with **over 70,000 patients treated in China** and proven efficacy in **three indications** there.  **[1817229_2144716_0]** 
- The company is prioritizing global Phase 3 development for **Myasthenia Gravis (MG)**, with its global trial expected to read out in **H1 2027**, and **Sjögren's disease**, where RemeGen recently reported Phase 3 success.  **[1817229_2144716_2]** **[1817229_2144716_3]** **[1817229_2144716_5]** 
- Vor Bio reported a cash balance of **$190 million as of June**, providing a runway into **Q1 2027**.  **[1817229_2144716_7]** 
- Upcoming catalysts include **48-week MG long-term data** at AANEM and **Sjögren's Phase 3 data** at a major rheumatology conference, both expected around the **end of October**.  **[1817229_2144716_4]** **[1817229_2144716_5]** **[1817229_2144716_7]**

Vor Bio Details Strategy for Telitacicept in Autoimmune Diseases

- Vor Biopharma Inc. is offering shares of its common stock with an aggregate offering price of up to **$119,699,305** through an at-the-market sales program.  **[1817229_0001193125-25-189169_d24419dex51.htm:0]** **[1817229_0001193125-25-189169_d24419d8k.htm:3]** 
- At a special meeting on **August 25, 2025**, stockholders approved the full issuance of common stock underlying outstanding warrants.  **[1817229_0001193125-25-189169_d24419d8k.htm:2]** 
- Stockholders also approved a series of alternate amendments to effect a reverse stock split in the range of **1-for-5 to 1-for-30**, though this has **not yet been effected** as of the report date.  **[1817229_0001193125-25-189169_d24419d8k.htm:2]** 
- Additionally, stockholders approved an amendment and restatement of the 2021 Equity Incentive Plan, increasing the number of shares reserved for issuance thereunder by **25,000,000 shares**.  **[1817229_0001193125-25-189169_d24419d8k.htm:1]** **[1817229_0001193125-25-189169_d24419d8k.htm:2]**

Vor Biopharma (VOR)